Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric AGvHD

Current Share Price Ascribes No Value to Chronic Heart Failure Potential, but Risk Still Very High

Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging

Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Equity Bottom-Up

<p>We are raising our fair value estimate for no-moat <a href="https://www.smartkarma.com/entities/769" target="_blank" data-smartkarma-citation="entities:769:1">Mesoblast Ltd (MSB AU)</a> to AUD 2.90 from AUD 2.60 previously, after adjusting for the recent weakness in the Australian dollar/ U.S. dollar exchange rate, which currently stands at 0.74. This is ahead of an expected readout of day 180 safety data from the ongoing phase 3 pediatric patients with steroidrefractory Acute Graft Versus Host Disease, or aGVHD, study of MSC-100-IV, in first-quarter fiscal 2019. However, our forecasts, which are…</p>

We are raising our fair value estimate for no-moat Mesoblast Ltd (MSB AU) to AUD 2.90 from AUD 2.60 previously, after adjusting for the recent weakness in the Australian dollar/ U.S. dollar exchange rate, which currently stands at 0.74. This is ahead of an expected readout of day 180 safety data from the ongoing phase 3 pediatric patients with steroidrefractory Acute Graft Versus Host Disease, or aGVHD, study of MSC-100-IV, in first-quarter fiscal 2019. However, our forecasts, which are…

Raising FVE for Mesoblast After Adjusting for AUD as We Await 180 Day Survival Data in AGvHD